Pharmacological Research (Sep 2023)

HPV E7-drived ALKBH5 promotes cervical cancer progression by modulating m6A modification of PAK5

  • Fu-Chun Huo,
  • Zhi-Man Zhu,
  • Wen-Qi Du,
  • Yao-Jie Pan,
  • Xin Jiang,
  • Meng-Jie Kang,
  • Bo-Wen Liu,
  • Jie Mou,
  • Dong-Sheng Pei

Journal volume & issue
Vol. 195
p. 106863

Abstract

Read online

Human papillomavirus (HPV) infection is a causative agent of cervical cancer (CC). N6-methyladenosine (m6A) modification is implicated in carcinogenesis and tumor progression. However, the involvement of m6A modification in HPV-involved CC remains unclear. Here we showed that HPV E6/7 oncoproteins affected the global m6A modification and E7 specifically promoted the expression of ALKBH5. We found that ALKBH5 was significantly upregulated in CC and might serve as a valuable prognostic marker. Forced expression of ALKBH5 enhanced the malignant phenotypes of CC cells. Mechanistically, we discovered that E7 increased ALKBH5 expression through E2F1-mediated activation of the H3K27Ac and H3K4Me3 histone modifications, as well as post-translational modification mediated by DDX3. ALKBH5-mediated m6A demethylation enhanced the expression of PAK5. The m6A reader YTHDF2 bound to PAK5 mRNA and regulated its stability in an m6A-dependent manner. Moreover, ALKBH5 promoted tumorigenesis and metastasis of CC by regulating PAK5. Overall, our findings herein demonstrate a significant role of ALKBH5 in CC progression in HPV-positive cells. Thus, we propose that ALKBH5 may serve as a prognostic biomarker and therapeutic target for CC patients.

Keywords